Literature DB >> 12385923

United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region.

Mary McNaughton Collins1, Michael J Barry, Anthony Zietman, Peter C Albertsen, James A Talcott, Elizabeth Walker Corkery, Diana B Elliott, Floyd J Fowler.   

Abstract

OBJECTIVES: To examine whether physicians' views on prostate cancer screening and treatment vary by geographic region in the United States.
METHODS: A mail survey was sent in 1998 to a random sample of physicians in the United States who were listed as radiation oncologists (response rate 76%, n = 559) and urologists (response rate 64%, n = 504) in the American Medical Association Registry of Physicians and practicing at least 20 hr/wk.
RESULTS: Radiation oncologists and urologists in Florida were more likely to report recommending routine prostate-specific antigen testing for men aged 75 years and older than were their colleagues in other regions of the United States. The Florida physicians were more likely to report treating at least 20% of their patients with brachytherapy and to report believing that brachytherapy has survival value for men with a less than 10-year life expectancy. No regional differences were found in the radiation oncologists' and urologists' beliefs about the survival value of radical prostatectomy; however, for men with a less than 10-year life expectancy, Florida urologists had more confidence in the survival benefit of external beam radiotherapy than urologists in other regions (P = 0.04). Radiation oncologists in Florida reported higher rates of recommending early androgen deprivation for a rising PSA after both radiotherapy and surgery (P = 0.008 and P = 0.001, respectively) than did their colleagues in other regions.
CONCLUSIONS: Florida radiation oncologists and urologists reported beliefs and practices that differed from their colleagues in other regions of the United States. Whether the distinctive style of prostate cancer diagnosis and treatment in Florida results in improved outcomes has yet to be proved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385923     DOI: 10.1016/s0090-4295(02)01832-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  The cost implications of prostate cancer screening in the Medicare population.

Authors:  Xiaomei Ma; Rong Wang; Jessica B Long; Joseph S Ross; Pamela R Soulos; James B Yu; Danil V Makarov; Heather T Gold; Cary P Gross
Journal:  Cancer       Date:  2013-10-04       Impact factor: 6.860

2.  Physician visits prior to treatment for clinically localized prostate cancer.

Authors:  Thomas L Jang; Justin E Bekelman; Yihai Liu; Peter B Bach; Ethan M Basch; Elena B Elkin; Michael J Zelefsky; Peter T Scardino; Colin B Begg; Deborah Schrag
Journal:  Arch Intern Med       Date:  2010-03-08

3.  Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions.

Authors:  Scott D Ramsey; Steven B Zeliadt; Catherine R Fedorenko; David K Blough; Carol M Moinpour; Ingrid J Hall; Judith Lee Smith; Donatus U Ekwueme; Megan E Fairweather; Ian M Thompson; Thomas E Keane; David F Penson
Journal:  World J Urol       Date:  2010-10-20       Impact factor: 4.226

4.  Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).

Authors:  Maria J Schymura; Amy R Kahn; Robert R German; Mei-Chin Hsieh; Rosemary D Cress; Jack L Finch; John P Fulton; Tiefu Shen; Erik Stuckart
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

5.  Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

Authors:  Ralph Madeb; Dragan Golijanin; Katia Noyes; Susan Fisher; Judith J Stephenson; Stacey R Long; Joy Knopf; Gary H Lyman; Edward M Messing
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

6.  Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey.

Authors:  Susan C Pitt; Nan Yang; Megan C Saucke; Nicholas Marka; Bret Hanlon; Kristin L Long; Alexandria D McDow; J P Brito; Benjamin R Roman
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.